Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts

Transplantation

Volumn 98, Issue 10, 2014, Pages 1056-1059

  Burbach, Maren ^a   Suberbielle, Caroline ^b   Brochériou, Isabelle ^a,c   Ridel, Christophe ^a   Mesnard, Laurent ^a,c   Dahan, Karine ^d   Rondeau, Eric ^a,c   Hertig, Alexandre ^a,c  

^a HÔPITAL TENON   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antibody mediated rejection; Complement; Eculizumab; Kidney transplantation

Indexed keywords

AUTOANTIBODY; COMPLEMENT C5 ANTIBODY; COMPLEMENT COMPONENT C1Q; CORTICOSTEROID; CREATININE; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIBODY; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ADULT; ANTIBODY MEDIATED REJECTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MEDICAL HISTORY; PATIENT ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA; RELAPSE; THROMBOCYTE COUNT; TREATMENT RESPONSE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; DONOR; GRAFT REJECTION; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; METABOLISM; TREATMENT FAILURE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT C1Q; COMPLEMENT C4B; COMPLEMENT C5; COMPLEMENT INACTIVATING AGENTS; FEMALE; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; PEPTIDE FRAGMENTS; TISSUE DONORS; TREATMENT FAILURE;

EID: 84927798214     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000184     Document Type: Article

References (16)

1. Lucas JG, Co JP, Nwaogwugwu UT, et al. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 2011;12:579.
2. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibodymediated rejection workshop. Am J Transplant 2011;11:896.
3. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007;83:1277.
4. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010;89:277.
5. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013;369:1215.
6. Racusen LC, Leffell MS. C1q-binding antibodies in kidney transplantation. N Engl J Med 2013;369:1266.
7. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405.
8. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21:1398.
9. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2008;9:231.
10. Ward PA. The harmful role of C5a on innate immunity in sepsis. J Innate Immun 2010;2:439.
11. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012;12:563.
12. Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med 2014;370:632.
13. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010;10:1812.
14. Jindra PT, Jin Y-P, Rozengurt E, et al. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008;180:2357.
15. Jindra PT, Jin Y-P, Jacamo R, et al. MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway. Biochem Biophys Res Commun 2008;369:781.
16. Naemi FMA, Carter V, Kirby JA, et al. Anti-donor HLA class I antibodies: pathways to endothelial cell activation and cell-mediated allograft rejection. Transplantation 2013;96:258.